查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046528

T細胞淋巴瘤市場－全球產業規模、佔有率、趨勢、機會與預測：按類型、治療方法、地區和競爭格局分類，2021-2031年

T-Cell Lymphoma Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Type, By Therapy, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球 T 細胞淋巴瘤市場預計將從 2025 年的 25.1 億美元大幅成長至 2031 年的 42.5 億美元，複合年成長率為 9.17%。

T細胞淋巴瘤是一群罕見且複雜的癌症，起源於T淋巴細胞，在非何傑金氏淋巴瘤中形成特定的亞型。市場成長的主要驅動力是全球血液系統癌症發生率的上升以及易患淋巴增生性疾病的老年人口的成長。此外，針對生技藥品和免疫療法的持續進步也是重要的商業性促進因素，為過去難以治療的疾病提供了創新治療方法。例如，美國癌症協會估計，到2025年，美國將新增80,350例非何傑金氏淋巴瘤病例，凸顯了針對各種類型非何杰金氏淋巴瘤的有效治療方法的迫切需求。

市場概覽
預測期 2027-2031
市場規模：2025年 25.1億美元
市場規模：2031年 42.5億美元
複合年成長率：2026-2031年 9.17%
成長最快的細分市場 放射治療
最大的市場 北美洲

然而，市場擴張的一大障礙是新治療方法的高成本。先進治療方法的高昂費用往往超出公共醫療體系的報銷能力，尤其是在新興國家。這種經濟障礙限制了患者獲得基本藥物的機會，使製造商的打入市場策略複雜化，並最終限制了有效臨床治療方法的商業化。

市場促進因素

先進的標靶治療和免疫療法正在改變全球T細胞淋巴瘤市場，使治療模式從傳統化療轉向精準醫療。這項創新包括新型作用機制，例如ITK抑制劑和雙特異性抗體，它們特異性針對難治性亞型中的分子路徑。鑑於該疾病的高死亡率，這些臨床進展至關重要。美國癌症協會估計，到2025年，美國將有19,390人死於非何傑金氏淋巴瘤，凸顯了開發更有效治療方法的迫切性。製藥公司正在推出強效新藥，例如Corvus Pharmaceuticals公司於2025年12月公佈了其sokeritinib治療T細胞淋巴瘤的I/Ib期臨床試驗的最終數據。在該試驗中，臨床實驗藥物sokeritinib在復發或難治性周邊T細胞淋巴瘤患者中顯示出令人鼓舞的結果，中位無惡化生存期為6.2個月，中位總存活期為28.1個月。

此外，皮膚T細胞淋巴瘤和周邊T細胞淋巴瘤發生率的不斷上升是推動市場成長的關鍵因素，持續刺激已通過核准生物製藥的需求。加之患者數量的增加和診斷能力的提升，加速了高價治療方法在全球範圍內的應用，顯著提升了市場領先企業的盈利。協和麒麟2025年11月發布的報告也反映了這一商業性趨勢，報告顯示，用於治療皮膚T細胞淋巴瘤的Poteligeo銷售額達到216億日元，年比成長14%，顯示市場對標靶免疫療法在治療這些棘手的骨髓惡性腫瘤日益成長的依賴。

市場挑戰

全球T細胞淋巴瘤市場面臨許多挑戰，其中最主要的障礙在於新型治療方法，尤其是基因改造T細胞療法的龐大成本。這些高昂的治療費用往往超出公共醫療體系的報銷限額。這種經濟差距不僅阻礙了合格的患者獲得必要的救命治療，也導致市場規模不斷萎縮。因此，由於醫療預算無法承擔如此昂貴的治療方法，製藥公司很難進入這個至關重要的市場。

這種經濟負擔直接阻礙了市場滲透，因為它給患者和醫療服務提供者都帶來了巨大的財務風險。例如，美國血液學會 (ASH) 在 2025 年報告中指出，約 29% 的 CAR-T 療法候選患者在初期就面臨經濟壓力，凸顯了經濟壓力阻礙治療啟動的現實。高昂的自付費用導致治療中斷率上升，也使得醫生不願開立昂貴的治療方法，最終阻礙了收入成長，並延長了研發公司的投資回收期。

市場趨勢

隨著新型生物標記的出現，全球T細胞淋巴瘤市場正經歷一場重大的策略轉型，這些標記可用於分層治療，從而將臨床治療方法從廣泛的組織學分類轉向精準的分子標靶治療。例如，在Sezary症候群和蕈狀肉芽腫中發現的KIR3DL2等標靶，正在加速創新精準生物製藥的研發。基於這些標記的患者分層能夠開發出個別化最佳化的細胞毒性抗體，從而提高對傳統治療無效患者的療效。 Innate Pharma公司在2025年5月發布的報告也印證了這一趨勢：其在臨床實驗抗體lactamab在多重抗藥性的Sezary症候群患者中取得了42.9%的總緩解率。

同時，抗體藥物複合體（ADC）的應用日益廣泛，尤其是在已通過核准的藥物在治療後期和適應症範圍不斷擴大的情況下，ADC正逐漸成為一種基礎治療方法。 CD30標靶偶聯物的持續商業性成功便是這一趨勢的有力佐證。這類偶聯物結合了單株抗體的精準性和細胞毒性有效載荷，能夠有效對抗標準化療常見的抗藥性。這些成熟治療方法的持續銷售成長凸顯了市場對偶聯物技術在治療侵襲性淋巴瘤亞型方面的依賴。正如FirstWord Pharma在2025年2月指出的那樣，CD30靶向ADC「Adcetris」在2024年第四季為輝瑞創造了2.85億美元的銷售額，這清晰地表明了市場對這類療法的強勁且持續的需求。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球T細胞淋巴瘤市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型（周邊{皮膚T細胞淋巴瘤、間變性大細胞淋巴瘤、血管免疫母細胞性T細胞淋巴瘤、其他}、淋巴母細胞性）
    • 治療方法（放射線治療、化療、免疫療法、幹細胞移植等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美T細胞淋巴瘤市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲T細胞淋巴瘤市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區T細胞淋巴瘤市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲T細胞淋巴瘤市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲T細胞淋巴瘤市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球T細胞淋巴瘤市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Acrotech Biopharma Inc.
  • Affimed GmbH
  • Bristol-Myers Squibb Company
  • Shenzhen Chipscreen Biosciences Co., Ltd.
  • Citius Pharmaceuticals, Inc
  • DAIICHI SANKYO COMPANY, LIMITED
  • Eisai Co., Ltd.
  • Genor Biopharma Co. Ltd
  • Innate Pharma SA
  • Digene Pharmaceuticals Co., Ltd.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16522

The global T-Cell Lymphoma Market is projected to expand significantly, from USD 2.51 Billion in 2025 to USD 4.25 Billion by 2031, demonstrating a compound annual growth rate (CAGR) of 9.17%. T-cell lymphoma, a rare and intricate group of T-lymphocyte-derived cancers, forms a specific subtype within non-Hodgkin lymphoma. This market's growth is largely driven by the increasing worldwide incidence of hematologic cancers and a growing elderly population more prone to lymphoproliferative disorders. Additionally, ongoing advancements in targeted biologics and immunotherapies are key commercial accelerators, providing innovative treatments for conditions previously resistant to therapy. For instance, the American Cancer Society estimated 80,350 new non-Hodgkin lymphoma diagnoses in the U.S. in 2025, highlighting the urgent demand for effective treatments across its diverse forms.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.51 Billion
Market Size 2031USD 4.25 Billion
CAGR 2026-20319.17%
Fastest Growing SegmentRadiotherapy
Largest MarketNorth America

However, a major hurdle for market expansion is the exorbitant cost of new treatment options. The high financial outlay for advanced therapies frequently surpasses the reimbursement capacity of public healthcare systems, especially in emerging economies. This economic barrier limits patient access to vital medications and complicates manufacturers' strategies for market entry, thereby restricting the commercial availability of effective clinical treatments.

Market Driver

Advanced targeted therapies and immunologics are transforming the global T-Cell Lymphoma Market, shifting treatment away from traditional chemotherapy towards precision medicine. This innovation includes new mechanisms like ITK inhibitors and bispecific antibodies, which specifically target molecular pathways in difficult-to-treat subtypes. Such clinical progress is crucial given the high mortality associated with the disease; the American Cancer Society reported an estimated 19,390 non-Hodgkin lymphoma deaths in the U.S. in 2025, underscoring the urgent need for more effective options. Pharmaceutical companies are introducing powerful new agents, demonstrated by studies such as Corvus Pharmaceuticals' December 2025 'Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial,' where the investigational agent soquelitinib showed promising median progression-free survival of 6.2 months and overall survival of 28.1 months in patients with relapsed or refractory peripheral T-cell lymphoma.

Furthermore, the increasing incidence of cutaneous and peripheral T-cell lymphomas acts as a significant market driver, fueling sustained demand for approved biologics. The expanding patient population, coupled with improved diagnostic capabilities, has accelerated the global adoption of premium-priced therapies, substantially boosting revenue for market leaders. This commercial trajectory is reflected in Kyowa Kirin's November 2025 report, which showed Poteligeo sales for cutaneous T-cell lymphoma rising 14% year-over-year to ¥21.6 billion, indicating a strengthening market reliance on targeted immunotherapies for managing these challenging hematologic malignancies.

Market Challenge

The global T-Cell Lymphoma Market faces substantial hurdles due to the prohibitive costs of novel treatments, notably genetically modified T-cell therapies, whose high prices often surpass the reimbursement limits of public healthcare systems. This financial discrepancy creates a critical barrier, denying eligible patients access to essential, life-saving interventions and consequently shrinking the viable market size. As a result, pharmaceutical manufacturers encounter difficulties entering crucial markets where healthcare budgets cannot support such expensive therapies.

This economic strain directly impedes market adoption by imposing considerable financial risks on both patients and healthcare providers. For instance, the American Society of Hematology reported in 2025 that approximately 29% of patients considered for CAR-T therapies experienced initial financial toxicity, underscoring how economic pressures deter treatment commencement. High out-of-pocket costs lead to increased treatment abandonment and physician reluctance to prescribe premium therapies, ultimately hindering revenue growth and extending the return on investment period for developers.

Market Trends

The global T-Cell Lymphoma Market is undergoing a significant strategic transformation with the emergence of novel biomarkers for stratified medicine, shifting clinical approaches from broad histological classifications to precise molecular targeting. This is evident in the discovery of targets like KIR3DL2, found in Sezary syndrome and mycosis fungoides, which facilitates the development of innovative precision biologics. Patient stratification based on these markers allows for the creation of customized, cytotoxicity-inducing antibodies, enhancing efficacy in patients who have not responded to previous treatments. Recent clinical findings support this, as Innate Pharma reported in May 2025 that their investigational antibody, lacutamab, achieved a 42.9% overall response rate in heavily pretreated Sezary syndrome patients.

Concurrently, the increasing adoption of Antibody-Drug Conjugates (ADCs) is establishing them as a foundational treatment, especially as approved agents gain traction in later lines of therapy and for broader indications. This trend is marked by the consistent commercial success of CD30-directed conjugates, which merge the accuracy of monoclonal antibodies with cytotoxic payloads to counteract resistance common in standard chemotherapy. The steady revenue growth of these established therapies confirms the market's dependence on conjugate technology for managing aggressive lymphoma subtypes, with Adcetris, a CD30-targeted ADC, generating $285 million in sales for Pfizer in Q4 2024, as noted by FirstWord Pharma in February 2025, illustrating the strong and continuous demand for this therapeutic class.

Key Market Players

  • Acrotech Biopharma Inc.
  • Affimed GmbH
  • Bristol-Myers Squibb Company
  • Shenzhen Chipscreen Biosciences Co., Ltd.
  • Citius Pharmaceuticals, Inc
  • DAIICHI SANKYO COMPANY, LIMITED
  • Eisai Co., Ltd.
  • Genor Biopharma Co. Ltd
  • Innate Pharma SA
  • Digene Pharmaceuticals Co., Ltd.

Report Scope

In this report, the Global T-Cell Lymphoma Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

T-Cell Lymphoma Market, By Type

  • Peripheral
  • Lymphoblastic

T-Cell Lymphoma Market, By Therapy

  • Radiotherapy
  • Chemotherapy
  • Immunotherapy
  • Stem Cell Transplantation
  • Other

T-Cell Lymphoma Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global T-Cell Lymphoma Market.

Available Customizations:

Global T-Cell Lymphoma Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global T-Cell Lymphoma Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Peripheral {Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angio-immuno-blastic T-cell Lymphoma, Other}, Lymphoblastic)
    • 5.2.2. By Therapy (Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, Other)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America T-Cell Lymphoma Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Therapy
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States T-Cell Lymphoma Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Therapy
    • 6.3.2. Canada T-Cell Lymphoma Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Therapy
    • 6.3.3. Mexico T-Cell Lymphoma Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Therapy

7. Europe T-Cell Lymphoma Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Therapy
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany T-Cell Lymphoma Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Therapy
    • 7.3.2. France T-Cell Lymphoma Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Therapy
    • 7.3.3. United Kingdom T-Cell Lymphoma Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Therapy
    • 7.3.4. Italy T-Cell Lymphoma Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Therapy
    • 7.3.5. Spain T-Cell Lymphoma Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Therapy

8. Asia Pacific T-Cell Lymphoma Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Therapy
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China T-Cell Lymphoma Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Therapy
    • 8.3.2. India T-Cell Lymphoma Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Therapy
    • 8.3.3. Japan T-Cell Lymphoma Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Therapy
    • 8.3.4. South Korea T-Cell Lymphoma Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Therapy
    • 8.3.5. Australia T-Cell Lymphoma Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Therapy

9. Middle East & Africa T-Cell Lymphoma Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Therapy
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia T-Cell Lymphoma Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Therapy
    • 9.3.2. UAE T-Cell Lymphoma Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Therapy
    • 9.3.3. South Africa T-Cell Lymphoma Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Therapy

10. South America T-Cell Lymphoma Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Therapy
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil T-Cell Lymphoma Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Therapy
    • 10.3.2. Colombia T-Cell Lymphoma Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Therapy
    • 10.3.3. Argentina T-Cell Lymphoma Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Therapy

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global T-Cell Lymphoma Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Acrotech Biopharma Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Affimed GmbH
  • 15.3. Bristol-Myers Squibb Company
  • 15.4. Shenzhen Chipscreen Biosciences Co., Ltd.
  • 15.5. Citius Pharmaceuticals, Inc
  • 15.6. DAIICHI SANKYO COMPANY, LIMITED
  • 15.7. Eisai Co., Ltd.
  • 15.8. Genor Biopharma Co. Ltd
  • 15.9. Innate Pharma SA
  • 15.10. Digene Pharmaceuticals Co., Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer